Article Text
Abstract
Elevated CA-125 levels have been reported in some women with endometrial carcinoma. Current follow-up policy for these patients does not involve the use of tumor markers. CA-125 measurements were performed in 28 patients with a diagnosis of endometrial cancer, 14 clinically free of disease and 14 with known disease. Based on the sensitivity (0.64) and specificity (0.93) observed we constructed a model to estimate the predictive value of the assay as a marker in the follow-up of patients who have completed treatment. This model would involve a CA-125 assay every six months for five years in 100 patients with stage I and II disease. Despite the high statistical correlation between the clinical status of the patient and the CA-125 value observed in our study, the positive predictive value would be approximately 24% in such a follow-up protocol where a low prevalence of recurrent malignancy is expected.
- CA-125
- endometrial cancer
- follow-up
- marker.